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Abstract: B a c k g r o u n d: Th e aim of this study was to evaluate morphometrically the pituitary 
adenomas immunoexpression.
M e t h o d s: Th e cases of 72 patients were analyzed, who underwent transsphenoidal surgery for pituitary 
adenomas. Subsequently, the immunohistochemical pituitary hormone panel was applied including alpha-
subunit of the glycoprotein hormones. Immunohistochemical sections were analyzed quantitatively with 
the help of morphometric grid. Th e percentage rate of the immunoexpression was calculated separately 
for every single hormone. 
R e s u l t s: As a result, 22 monohormonal adenomas (30.56%), 21 plurihormonal adenomas (29.17%), 21 
immunonegative adenomas (29.17%) and 8 unreliable cases (11.11%) were recognized. Th e immunopositivity 
for particular hormones was found as follows: PRL and GH (25% each), α-SU (22.22%), ACTH (13.89%), 
LH and FSH (12.5% each), and TSH (5.56%). An average percentage of immunoexpression in each positive 
staining groups occurred as follows: for PRL — 59.98%, for GH — 53.97%, for ACTH — 39.21%, for TSH 
— 25.05%, for LH — 37.3%, for FSH — 54.66%, for α-SU — 45.71. 
C o n c l u s i o n: Th e morphometrical method utilizing the immunoexpression index introduced in this 
study provided a very precise recognition of pituitary adenomas pathology. Th is method may limit the 
subjectivity of a single researcher and enable better comparison of the studies. Th e plurihormonality is 
a common phenomenon, and immunohistochemical staining for all adenohypophyseal hormones is 
obligatory in order to classify pituitary adenomas correctly. Th e awareness of an operating neurosurgeon of 
the importance of meticulous collecting histopathological material, especially in microadenoma cases, has 
essential impact on further neuropathological evaluation and possibility of immunohistochemical staining. 
Key words: morphometrical method, immunohistochemical techniques, adenohypophyseal hormones.
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Introduction
Basic neuropathological evaluation of pituitary adenomas involves the assessment 
of hematoxylin and eosin (H&E) stained preparations. Historically pituitary 
adenomas were classed as either chromophobic and acido- or basophilic due 
to its affi  nity for stains hematoxylin and eosin, as in the case of normal pituitary 
cells [1]. Th e immunohistochemical studies have completed the neuropathological 
diagnostics of pituitary adenomas [2–4]. Th e reliable marker of the presence of 
pituitary adenoma is at least focally positive staining for the trophic hormones 
[5]. Th e immunohistochemical techniques based on the use of antibodies against 
the pituitary hormones: PRL, GH, ACTH, TSH, FSH, LH, α-SU [5–8] are now 
widely applied. However there is a paucity of knowledge on the methods of 
immunohistochemical results assessment and its clinical utility [9]. Most oft en, in 
practice, descriptive approach is applied, based on the interpretation of examining 
neuropathologist. Th erefore this method is highly subjective, dependent on the 
experience of the investigator. Some authors introduce the rating scales grading the 
strength of immunohistochemical staining, for example: 0, 1+, 2+, 3+, etc. [10–12]. 
Both, qualitative and semiquantitative assessment, does not show the strength 
of the adenoma’s hormonal expression. Further the preparations with weak or 
dispersed expression result in the additional major problem [13]. Th e recognition 
of such reactions as positive seems controversial. Some authors defi ne additionally 
the minimum expression at which the reaction is considered to be positive [4, 7, 
12, 14, 15]. Hence the proper selection of method to morphometric evaluation of 
immunohistochemical scans remains essential. 
In this study we present quantitative evaluation of the expression of pituitary 
adenomas hormones.
Material and Methods
Patients treated in the Department of Neurosurgery and Neurotraumatology of 
Jagiellonian University Medical College in Krakow between 2007 and 2016 and 
diagnosed in the Department of Neuropathology were enrolled into the study. Final 
study group consisted of 44 women and 28 men aged between 10 and 84 years (mean 
age 47 years) with complete clinical, histopathological and radiological medical 
records. Th is study was conducted in accordance with the ethical standards laid 
down in the Declaration of Helsinki (1964) and its design was approved by the local 
University Ethical Committee (protocol number KBET/157/B/2012).
Medical history, neurological examination fi ndings and trophic hormones serum 
levels led to the diagnosis of endocrine impairments (Fig. 1). 
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According to MRI data: macroadenomas were diagnosed in 51 (70.84%) cases, 
while microadenomas were found in 21 (29.16%) cases. 
All patients were operated on microsurgically using a transsphenoidal approach.
Th e entire panel of immunohistochemical tests for adenohypophyseal hormones 
(PRL, GH, ACTH, TSH, LH, FSH, α-SU) was conducted in all patients. Th e proper 
execution of staining was confi rmed by performing control staining on preparations 
of the pituitary gland of the section material. Table 1 summarizes the characteristics 
of each hormone staining.
Th e diagnosable tissue areas on the H&E preparations were calculated. All sections 
were examinated using light microscope Nikon Optishot-2 under magnifi cation of 
200× and 400×. Nondiagnostic areas, meaning those where there was no adenoma 
tissue and the presence of regular pituitary tissue, fi brosis, hemorrhagic stroke, etc. 
were identifi ed, were excluded from the analysis. Th e morphometric evaluation was 
undertaken if at least one fi eld of view under 200× magnifi cation included adenoma 
tissue without evidence of electrothermal or mechanical damage and no massive 
necrotic lesions and/or bleeding was detected in this area. If the preparation wasn’t 
suitable for the assessment the next section was cut and the staining was repeated. 
To assess the expression of the hormones the cell index was used. Under the light 
microscope 400× magnification the percentage of cells presenting the positive 
immunohistochemical reaction was calculated. Morphometric analysis was performed 
Fig. 1. Endocrinological diagnoses. 
* CNFPAs — Clinically non-functioning pituitary adenomas.
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Table 1. Immunohistochemical staining. 
Antibody Manufacturer Dilution Incubation Reaction visualization Comments
anti-PRL Dako, Denmark ready to use
15 min., 
room temp.
EnVISION TM + System 
Labelled Polymer HRP-
ant rabbit
–
anti-GH Dako, Denmark ready to use
15 min., 
room temp.
EnVISION TM+ System 
Labelled Polymer HRP-
ant rabbit
–
anti-
ACTH Dako, Denmark
ready to 
use
15 min., 
room temp.
EnVISION TM+ System 
Labelled Polymer HRP-
ant rabbit
–
anti-TSH Novocastra, UK 01:25 24 hours, 4°C
ABC KIT Vectastain 
Universal
unmasking 
antigen by 
2 × 5 min. in 
buff er pH = 6.0
anti-LH
anti-FSH Dako, Denmark 01:25
30 min., 
room temp.
EnVISION TM+ System 
Labelled Polymer HRP-
ant mouse
unmasking 
antigen by 
2 × 5 min. in 
buff er pH = 6.0
anti-α-SU Novocastra, UK 0.100 24 hours, 4°C
ABC KIT Vectastain 
Universal
unmasking 
antigen by 
2 × 5min. in 
buff er pH = 6.0
Fig. 2. Morphometric grid.
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manually using morphometric adapter to an optical microscope and morphometric 
grid (Fig. 2). Morphometric grid used in the study consisted of 16 fi elds of equal 
area (covering the entire fi eld of view in the microscope under 400× magnifi cation). 
Staining cells and all cells number were counted in every fi eld. Th e analyses was 
performed systematically in 5 reliable (free from artifacts) parts of preparation. Th is 
way the precise quantitative immunohistochemical analysis of pituitary adenomas 
were carried out. 
A small number of dispersed positive cells situated on the perimeter of adenoma 
presenting a positive IHCH reaction was not counted because it was considered as 
impurity of “trapped” normal cells adenohypophysis.
All calculations and statistical analyzes were performed using the statistical 
package STATISTICA 9 PL licensed for the Jagiellonian University.
Results
In the study group of 72 patients 43 had positive immunohistochemical reactions. 
22 monohormonal adenomas (30.56%), 21 plurihormonal adenomas (29.17%), 21 
immunonegative adenomas (29.17%) were diagnosed. In 8 cases (11.11%) investigators 
haven’t been able to interpret immunohistochemical reactions, these results were 
considered unreliable. Th e interpretative diffi  culties was caused mainly by presence of 
hemorrhage, necrosis, thermal artifacts, adeno- or neurohypophysis. 
Th e smallest fi eld of the tissue in the preparation was 0.55 mm² and the biggest 
—  156.15 mm²; the average fi eld analyzed was 41.79 mm² (standard deviation of 
37.79). Th ere were no threshold admitted for labeling index. Th e smallest positive 
reaction observed was 4.3% for TSH in plurihormonal adenoma.
Positive reaction towards the prolactin and growth hormone were detected in 18 
cases (25%), alpha subunit 16 (22.22%), adrenocorticotropic hormone in 10 (13.89%), 
LH in 9 (12.5%), FSH in 9 (12.5%) and thyroid-stimulating hormone in 4 cases 
(5.56%), respectively.
84 out of 504 evaluated immunohistochemical preparations among 72 cases have 
been found positive for the various hormones presence.
Among these 84 positive immunohistochemical preparations a total of 113 512 
cells were counted of which 61 008 were considered as positive. Th e immunoexpression 
percentage of all positive reactions was calculated (Table 2 and 3). The average 
number of all cells in a single fi eld of view under 400× magnifi cation was 14.47, the 
average number of positive cells per fi eld of view of 400× was 7.8. Th erefore, for the 
entire group the average immunoexpression index reached 53.76.
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Table 2. Th e immunoexpression in monohormonal adenomas1.
PRL (8)1 GH (7) ACTH (2) TSH (0) LH (1) FSH (1) α-SU (3)
84.8% 61.0% 45.0% 34.6% 19.1% 14.6%
58.7% 14.7% 41.3% 27.1%
85.1% 73.8% 70.0%
72.7% 74.6%
59.2% 69.1%
25.1% 75.1%
82.3% 85.5%
86.8%
1 in parentheses, the number of cases of specifi ed type of monohormonal adenomas were notifi ed
Table 3. Th e immunoexpression in plurihormonal adenomas.
No PRL GH ACTH TSH LH FSH α-SU Total
1 16.9 69.7  86.6
2 55.2 87.4 142.6
3 66.3 88.3 154.6
4 75 11.6  86.6
5 61.9 37 71.2 170.1
6 26.6 80.8 107.4
7 17  8 53 24.1 102.1
8 85.8  9.7  95.5
9 50.3 57.2 46.8 77.9 232.2
10 27 83.1 10.2 120.3
11 47 34.6 47.5 85.7 214.8
12 60.5 70.7 24 28 53.9 77.9 315
13 44.9 52.3 41.1 138.3
14 53.1 58.6 45.5 157.2
15 71.2 34.7 60.2 166.1
16 78 32.5 35.8 43.3 74.3 263.9
17  7.1 87.5  94.6
18 12 17.9  29.9
19 41.1 63.5 15.4 76.8 196.8
20 15.4 44.6  60
21 84.1  4.3  88.4
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Discussion
Immunohistochemical staining in the diagnostics of pituitary adenomas enables their 
proper classifi cation, verifi cation of the presence of the pituitary adenoma, and in 
some cases the diff erential diagnosis of other lesions located in the sella turcica region 
[16]. In view of the increased aggressiveness of certain adenomas immunophenotypes 
immunochemical staining is important for the determination of prognosis [2, 17, 
18]. In the discussion on the results of immunohistochemical staining arise two 
major problems of samples validity and evaluation methods of preparation. Th e 
morphometric method applied in this study allows for qualitative and quantitative 
assessment. Th e accuracy of immunohistochemical testing brings us closer to the 
knowledge about the true nature of adenoma. In this study, special attention was 
paid to the methodology. In the fi rst place H&E preparations were evaluated and the 
reliable regions were selected. In the second place the immunohistochemical results 
were analyzed excluding normal cells of adenohypophysis. Th en, fi nally, hormone 
expression was evaluated by counting all positive reacting cells in relation to all cells 
in the adenoma in fi ve consecutive preparation fragments. Th us, the percentage of 
immunoexpression was calculated. Comparing results of other authors a special 
attention was drawn to the manner of immunohistochemical analysis. Literature 
data suggest that the selected method of immunohistochemical preparations 
assessment might be crucial. Few studies discuss the methods applied to assess 
immunohistochemical results and reliability of the biological material, while those 
available vary considerably. Th us, comparing the results of immunohistochemical 
studies of pituitary adenomas is not easy due to the very diverse methodology of the 
research. In routine practice, the result of immunohistochemical testing determines, 
usually, only whether the reaction is positive or negative [19]. Th is result is usually 
accompanied by an optional comment (which may be regarded as a descriptive 
analysis), what is highly subjective. In the literature, various quantitative [7, 20–22] 
and semiquantitative [10–12, 23] (in arbitrarily adopted degrees) methods of 
immunohistochemical evaluation exist trying objectivize this issue. Th e question is 
how to defi ne the various degrees of immunoexpression. In practice, the specifi c 
categorizations have depended on the individual preferences of the investigator. 
Accordingly, the results have diff ered from each other because they haven’t been 
standardized [24]. Table 4 demonstrates how inconsistent is the presentation of the 
results by diff erent authors [7, 9–12, 14, 19–21, 23–29]. Moreover, not all researchers 
included detailed description of method used for immunohistochemical evaluation. 
Th e problem is certainly the lack of clear standards [9]. In the literature, there is no 
defi nition of what exactly is a positive immunohistochemical reaction [9] and the 
comparison of results is diffi  cult due to various cut-off  points. Discrepancies due to 
diff erent percentage of positive cells indicating positive reaction may lead to large 
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Table 4. Th e methods for immunohistochemical evaluation in the literature.
Author Year t1 Antibodies Method Comments
Knosp et al. [25] 1988 nd2 polyclonal qualitative and semiquantitative
0, +, ++, +++, scale 
depending on the number of 
positive cells and intensity 
of staining, one investigator
Herzog et al. [20] 1993 4 μm polyclonal percentage of immunoexpression
morphometric grid 100 × 
100 μm
Matsuo et al. [24] 1995 3 μm polyclonal
quantitative 
— manual counting 
vs computer 
analysis
50 fi elds in preparation, the 
amount of positive reacting 
cells in the fi eld, evaluation 
of staining intensity in 
pictures analyzer
Gsponder et al. [7] 1999 nd nd semiquantitative weak reaction if 10–50%,strong reaction if >50%
Zhao et al. [26] 2000 nd polyclonal
quantitative 
— percentage of 
immunoexpression
1000 cells were tested 
in preparation, cut-off  
point = 5%
Ho et al. [23] 2001 nd monoclonal semiquantitative <5%+, 5–20%+, 20–50%, >50%+
Münscher et al. [12] 2001 nd nd semiquantitative
1+, 2+, 3+,
the level of reaction 
reliability >20%
Kojima et al. [11] 2002 4–6 μm polyclonal semiquantitative 1–24%+, 25–74%+, >75%
Gołkowski et al. 
[19] 2003 5 μm polyclonal qualitative +/–
Mahta et al. [7] 2007 nd polyclonal
quantitative 
— percentage of 
immunoexpression
cell counts of three 
fi elds with the largest 
immunoexpression (hot 
spots), cut-off  point >5%
Yamada et al. [21] 2007 nd polyclonal/monoclonal
quantitative 
— percentage of 
immunoexpression
manual counting by 
technician
Hamid et al. [9] 2009 nd monoclonal
semiquantitative, 
with analysis of 
reaction intensity
1+: <1% strong+ or 
<10 weak+,
2+: 1–10% strong + or 
10–50% weak+, 
3+: 10–50% strong + or 
50–75% weak+, 
4+: 50–75% strong + or 
>75% weak+, 
5+: >75% strong +
evaluation of all 
preparations by one 
investigator not knowing 
the clinical data of patients
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diff erences in the results [16]. In this study, no criteria were applied for the smallest 
percentage of immunoexpression to recognize the authentically positive reaction. 
However it was verifi ed if the sparse, diff use expression hasn’t resulted from the 
presence of trapped normal pituicytes. Th e smallest value of immunoexpression in 
this study was 4.3% for the reaction indicating TSH. Some authors provide manual 
analysis of immunoexpression [21, 25] some relayed on the automatic analysis with 
use of pictures analyzer [24]. Matsuo et al. studied a pituitary adenomas in rats [24]. 
Th ey compared the concentrations of prolactin and growth hormone in the adenomas 
tissue with the results of immunohistochemical analysis obtained manually and with 
use of pictures analyzer. Th e results indicated a strong correlation between hormone 
concentration and the immunohistochemical image with much greater strength of 
relation using computer image analysis. Th e authors of this study explain this by the 
greater capability of equipment to assess immunointensity of the image [24]. Th e 
accuracy of computer equipment is unquestionable and outperforms human capacity 
[30]. However, in case of immunohistochemical image analysis, in particular for 
a  surgical material, which for obvious reasons can’t be technically perfect, collected 
and prepared in a strictly reproducible and homogenous manner (as it is the case 
of the experimental study) caution is essential in terms of the so-called background 
reaction, which may be considered as the weak positive reaction. In addition, the 
selection the fragment of the preparation suitable for the analysis can be done only 
by a person trained in the assessment of immunohistochemical preparations. Pictures 
analyzer is not able to distinguish trapped adenohypophysis cells, is not critical to the 
Author Year t1 Antibodies Method Comments
Pawlikowski et al. 
[14] 2010 nd
polyclonal/
monoclonal nd
the level of reliability of 
reaction >1%
Balinisteanu et al. 
[27] 2011 nd monoclonal
qualitative and 
quantitative 
immunoreactivity to 
diff erent hormones 
estimated as positive or 
negative; the Ki-67 labeled 
index (LI) was assessed by 
counting the percentage of 
number of positive
Oriz-Plata et al. [28] 2012 nd monoclonal semiquantitative 
0 (negative), 
1+ (10–30% of cells), 
2+ (30–50% of cells) or 
3+ (over 50% of cells).
Cimpean et al. [29] 2015 3 μm polyclonal/monoclonal qualitative three investigators
1 t — the thickness of the scrap
2 nd — no data
Table 4. Cont.
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artifacts, and it is not able to narrow the area of analysis to the reliable regions of the 
preparation [31]. On the other hand, some authors limited the analyzed fragments 
of the preparation only to the places with the highest expression (hot spots), that 
leads to the overestimation the result of quantitative evaluation. In this study, we 
haven’t limited the analysis to the fi elds with the highest expression evaluating the 
available, reliable material in a systematic way. In the literature it is emphasized 
the importance of antibodies used in the experiment [16]. Th e use of monoclonal 
antibodies, in contrast to polyclonal, leads to lower frequency of positive reactions 
identifi cation for greater number of hormones and increases the percentage of 
immunoexpression specifi c for a particular adenoma type [9, 16]. In this study, the 
polyclonal antibodies available in the local Laboratory of Neuropathology were used. 
Th e choice of a particular type of antibody also depends on the quoted market prices 
and the quality of the reactions. Matsuo et al. also point out the validity of staining 
of all preparations in the same session under constant conditions [24]. Th e thickness 
of the scrap, not considered by all the authors, may also aff ect the obtained results 
[30]. Th eoretically, the thicker the preparation the more cells may be found in the 
section [31].
In the study group 59.73% of pituitary adenomas presented positive immuno-
histochemical reaction for one or more hormones. 29.17% hormonally inactive pituitary 
adenomas were diagnosed. Presented distribution of adenomas is characteristic for the 
surgical series, where a large group are patients with advanced neurological symptoms 
caused by the expansion of hormonally inactive macroadenoma [32]. 11.11% of 
preparations were of the quality that was to poor for interpretation. Th ey were found 
to be unreliable at the stage of neuropathological examination, what means at least 
the H&E preparation that enabled the pituitary adenoma recognition. Aft er adjusting 
for cases where the material was completely damaged or extremely poor and did not 
allow for the preparation of a suffi  cient number of scraps for testing, then the actual 
number of unreliable cases is even greater. Analyzed literature reports don’t present 
any data on the number of unreliable tests. Th is surprisingly high percentage of non-
representative preparations aff ects the relationship between immunohistochemical 
results and clinical picture.
Positive reactions for prolactin and growth hormone were diagnosed the most 
oft en, stating in 25% of patients each. Most studies on immunohistochemistry in 
pituitary adenomas also provide the greatest incidence of these same reactions [1, 
5, 33]. Th e third most frequently observed positive immunohistochemical reaction 
was for the alpha-subunit (22.22% of patients). The common presence of this 
reaction can be explained by the fact that pituitary glycoprotein hormones include 
α-SU and it may be identified independently of these hormones [34, 35]. The 
study of Knosp et al. positive reactions to the alpha subunit was present in 10% of 
cases [25], in Maksymowicz study —  in 6.49% of cases [36]. Positive reaction for 
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ACTH were found in 13,89% of cases. Maksymowicz showed a 24.2% incidence of 
ACTH reaction in the larger study group of 154 patients [36]. Both, LH and FSH, 
were immunohistochemically detected in 12.5% of cases. These reactions were 
found among clinically inactive pituitary adenomas and as admixture in some 
of plurihormonal adenomas. By comparison in Maksymowicz study LH positive 
reaction was found in the 6.49% of cases and FSH in 5.19%. In the Knosp study 
among gonadotropins only reaction for LH was determined and its incidence was 
1.21% [25]. In our study the least oft en found reaction was for TSH (5.56%). Th is 
corresponds to the least often diagnosed according to WHO data thyrotrophic 
adenoma [37, 38]. Gołkowski et al. in the study on the similar subject conducted 
immunohistochemical staining but only for the four hormones — PRL, GH, ACTH, 
TSH [19]. Th e incidence of expression of particular hormones in the study group is 
diff erent from the values obtained in this study and was 42.5% for PRL, 35% for GH, 
40% for ACTH 40% and 17.5% for TSH [19]. Diff erences result probably of small 
numbers of investigated series [25].
Detection of positive reaction does not authorize yet to identify a particular 
adenoma type. This is related to the possibility of expression of more than one 
hormone that occurs in case of plurihormonal adenomas. In this study, only one of 
the hormone overproduction resulted in the clinical manifestation. Th is is confi rmed 
by studies on plurihormonal adenomas [3, 14, 17 23]. On the other hand, some of 
hormonally inactive adenomas presented the positive immunoexpression. A similar 
phenomenon has been reported by the other authors of studies on hormonally 
inactive adenomas [7, 33, 35, 39].
Morphometric immunohistochemical evaluation with use of the immunoreactivity 
index enables very precise recognition of the pituitary adenoma pathology, reduces 
errors due to the subjectivity of investigator assessment and enables the objective 
comparison of results. Th is method should become a standard in the histopathological 
diagnostics of pituitary adenomas.
Plurihormonal adenomas are the common phenomenon among the pituitary 
adenomas. Immunohistochemical staining for all the pituitary trophic hormones are 
necessary for appropriate classifi cation of pituitary adenomas.
Th e special attention of neurosurgeon to secure biological material, especially 
in case of microadenoma, is crucial and causes significant impact on further 
neuropathological diagnosis and the ability to perform immunohistochemical 
staining. 
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